Abstract
The hypotheses emerging from basic research on colorectal liver metastases must be tested in clinical situations for the adaptation of current treatment strategies. Pre-metastatic niches have been shown to exist in human colorectal synchronous metastases, with the liver parenchyma adjacent to the synchronous liver metastases providing a favorable, angiogenic environment for metastatic tumor growth. The role of the VEGF signaling pathway in liver regeneration and tumor growth remains unclear, but the use of antiangiogenic agents in combination with surgical treatment is almost certainly beneficial.
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology
-
Cell Movement
-
Clinical Trials as Topic
-
Colorectal Neoplasms / metabolism
-
Colorectal Neoplasms / pathology*
-
Combined Modality Therapy
-
Endothelial Cells / metabolism
-
Endothelial Cells / pathology
-
Humans
-
Inhibitor of Differentiation Protein 1 / genetics
-
Inhibitor of Differentiation Protein 1 / metabolism
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary
-
Liver Neoplasms / surgery*
-
Liver Regeneration
-
Neovascularization, Pathologic / metabolism
-
Neovascularization, Pathologic / pathology*
-
Postoperative Complications / drug therapy
-
Postoperative Complications / pathology
-
Signal Transduction
-
Tumor Microenvironment*
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism*
-
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
-
Vascular Endothelial Growth Factor Receptor-2 / genetics
-
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Substances
-
Antineoplastic Agents
-
ID1 protein, human
-
Inhibitor of Differentiation Protein 1
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Vascular Endothelial Growth Factor Receptor-2